Surgical Innovations Group plc
("Surgical Innovations", "SI" or the "Company")
Posting of 2021 Annual Report & Accounts
Notice of Annual General Meeting
Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery ("MIS"), confirms that the Annual Report and Accounts for the year ended 31 December 2021 ("2021 Annual Report") and the Notice of the 2022 Annual General Meeting ("AGM") have now been published and can be accessed via the "Investor Centre" section of the Company's website at: www.sigroupplc.com
The 2021 Annual Report, the Notice of AGM and details voting by proxy will be posted to shareholders who have not consented to receive electronic communications.
Notice of AGM
The AGM is to be held on Monday 27 June 2022 at 10:00 am at the Company's offices at Clayton Wood House, 6 Clayton Wood Bank, Leeds, LS16 6QZ and will consider the Resolutions set out in the Notice of AGM.
We encourage shareholders to participate in the AGM by voting by proxy. As it is not always possible to attend and ask questions in person, we will provide an opportunity for shareholder engagement prior to the AGM. In order to facilitate this, if you are a shareholder and would like to ask the Board a question, please submit your questions to the following email: si@surginno.co.uk, titled 'AGM'. Shareholders should note that any questions in relation to confidential or potentially price sensitive matters cannot be addressed.
The proxy appointment form should be returned, or the electronic proxy appointment instruction transmitted, no later than 10:00 am on Thursday 23 June 2022. More details can be found in the Notice of AGM.
For further information please contact:
Surgical Innovations Group plc | www sigroupplc com | ||
David Marsh, CEO | Tel: 0113 230 7597 | ||
Charmaine Day, CFO | | ||
| | | ||
Singer Capital Markets (Nominated Adviser & Broker) | Tel: 020 7496 3000 | ||
Aubrey Powell / Rachel Hayes | | ||
| | | ||
Walbrook PR (Financial PR & Investor Relations) | Tel: 020 7933 8780 or si@walbrookpr.com | ||
Paul McManus / Lianne Applegarth | Mob: 07980 541 893 / 07584 391 303 | ||
About Surgical Innovations Group plc
The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.
We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part reusable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.
Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.
In addition, we design and develop medical devices for carefully selected OEM partners and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.
We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs in the operating theatre environment.
Further information
Further details of the Group's businesses and products are available on the following websites:
To receive regular updates by email, please contact si@walbrookpr.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.